Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients

Mostrar otras versiones (1)

BACKGROUND: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). However, reports of its use and subsequent fatal arrhythmias in patients with coronavirus disease 19 (COVID-19) have raised concern regarding its cardiovascular (CV) sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Elizabeth, Giles, Jon T., Perez-Recio, Thania, Pina, Paloma, Depender, Christopher, Gartshteyn, Yevgeniya, Askanase, Anca D., Bathon, Joan, Geraldino-Pardilla, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554185/
https://www.ncbi.nlm.nih.gov/pubmed/34715924
http://dx.doi.org/10.1186/s13075-021-02646-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554185/
https://www.ncbi.nlm.nih.gov/pubmed/34715924
http://dx.doi.org/10.1186/s13075-021-02646-0

Ejemplares similares